[Conservative therapy of arterial occlusive diseases. Double-blind study on the effect of butalamine hydrochloride].
In a double blind placebo-controlled trial the influence of butalamine-hydrochloride (Adrevil forte) in a daily dosage of 3 x 2 tablets on the exercise tolerance of muscles with impaired blood flow in the lower limb was evaluated. The drug was tested versus placebo in a total of 32 patients suffering from peripheral arterial insufficiency stadium II according to Fontaine with occlusions in one or both extremities. Clinical parameters measured were muscle ergometry, plethysmography as well as the assessment of the painfree walking distance. During the whole trial the systemic blood pressure was monitored. The group receiving the active drug showed already after two weeks therapy a statistically significant improvement in the walking distance. After the end of 8 weeks therapy the walking distance in the group under active drug therapy was increased 4 times. Measurements of perfusion also showed significantly higher values under active therapy. The systemic blood pressure was not affected during the 8 weeks therapy with Adrevil forte.
D000328:Adult; D000368:Aged; D001157:Arterial Occlusive Diseases / Q000188:drug therapy*; D001794:Blood Pressure / Q000187:drug effects; D004311:Double-Blind Method; D004341:Drug Evaluation; D004361:Drug Tolerance; D006801:Humans; D007383:Intermittent Claudication / Q000188:drug therapy; D008875:Middle Aged; D010069:Oxadiazoles / Q000627:therapeutic use*; D010919:Placebos
D010069:Oxadiazoles; D010919:Placebos
Zur konservativen Therapie arterieller Verschlusskrankheiten. Doppelbind-Studie zur Wirkung von Butalaminhydrochlorid.